SUMMARY AT A GLANCE
Calciphylaxis (or calcific uraemic arteriolopathy) is an uncommon condition that generally affects patients with chronic kidney disease. Management is challenging and there is a paucity of evidence-based therapeutic options. This systematic review assesses the evidence (case reports and case series) for the use of sodium thiosulfate in the treatment of calciphylaxis.
ABSTRACT:
Aim: Calciphylaxis is a severe complication of advanced chronic kidney disease (CKD). Sodium thiosulphate (STS), an antioxidant and calcium chelating agent, has been used for the treatment of calciphylaxis. However, its efficacy and safety have not been systematically analysed and evaluated.
Methods: MEDLINE, EMBASE, and the Cochrane Library database were systematically searched for case report or cases series on use of STS for calciphylaxis published between July 1974 and October 2016. We extracted data on clinical characteristics, laboratory tests result and medication use. The effective treatment was defined as improvement in skin lesion cicatrisation or pain relief without death. Non-responding effects were defined as stable skin lesions without remission or exacerbation of the disease in patients who remained alive. All-cause mortality after STS treatment was defined as death due to exacerbations of calciphylaxis or other complications of advanced CKD. We compared the baseline parameters of the patients as well as the efficacy and mortality of the STS therapy between case report and multi-case reports. Statistical analyses were performed using SPSS 19.
Results: A total of 83 papers were screened, 45 of them (n = 358) met the inclusion criteria, including 36 case reports (n = 64) and nine multi-case reports (n = 294). The mean age of the patients with calciphylaxis was 58 ± 14 years (range 26-91 years). They were female predominant, accounting for 74.1%. Among the patients with calciphylaxis, 96.1% patients were on dialysis with median dialysis vintage of 44.5 months (range 24-84 months). STS was effective in 70.1% of patients, 37.6% patients died. The proportion of patients with sepsis was higher among those who received intravenous STS. There was no significant difference in efficacy between the different STS administration methods (P = 0.19).
Conclusion:
Although the study was unable to assess the efficacy of sodium thiosulphate alone in the treatment of calciphylaxis, it still reveals a promising role of STS as an effective therapy for calciphylaxis. Further prospective studies to define the optimal therapy for calciphylaxis are needed.
Calciphylaxis is a severe pathological process in patients with advanced chronic kidney disease (CKD) and is a potential predictor of cardiovascular death in long-term haemodialysis patients. [1] [2] [3] The estimated prevalence of dialysis-related calciphylaxis is approximately 4% in haemodialysis (HD) patients and less than 1% in predialysis CKD patients. 4, 5 Calcium and phosphorus imbalance is a key risk factor for calciphylaxis. Calciphylaxis frequently results in severe ischaemia and sepsis, which is associated with poor prognosis. The mortality rates in dialysis patients with calciphylaxis are almost three times higher than those without calciphylaxis as reported in the United States Renal Data System. 6 However, its management remains a clinical challenge. Sodium thiosulfate (STS), also known as sodium hydrosulfite, is an antioxidant. In recent years, STS has been successfully used off-label in some diseases related to calcium overload, such as kidney stones, calcification of soft tissue and uraemic small-artery disease (calcific uraemic arteriolopathy [CUA] also known as calciphylaxis). 7, 8 However, there is conflicting evidence about the efficacy and safety of STS for the treatment of calciphylaxis. 9 This systematic review aimed to assess the efficacy and safety of STS among patients with calciphylaxis.
METHODS
Data sources and searches MEDLINE, EMBASE, and the Cochrane Library database were systematically searched using relevant keywords including "sodium thiosulphate" and "calciphylaxis" without language restriction.
Study inclusion and data extraction
We searched for case report or cases series describing the effects of STS therapy for the treatment of calciphylaxis published between July 1974 and October 2016. References list of case reports were also hand searched. We extracted the following information: (i) patient characteristics (age, gender, dialysis modality and vintage); (ii) primary causes of CKD (diabetes mellitus, hypertension, glomerulonephritis, or other complication); (iii) biochemical and haematological parameters (the serum calcium, phosphorus and parathyroid hormone (PTH)); (iv)calcifications location; (v) STS treatment schedule (administrative ways and dosage, use in combination with other medications and treatment effectiveness) and patients' clinical outcomes. Missing data were obtained by contacting the original authors. Case reports were defined as individual patients with detailed baseline characteristics reported. Multiple case reports were defined when aggregated data were reported from multiple patients in case series. Only the data that were clearly stated in the literature were extracted. For case reports, we extracted the individual data and combined the type of calcifications and STS regimens. For multi-case reports, we extracted the average value of age, calcium and phosphorus of patients. We compared the patients' baseline parameters as well as the efficacy and mortality of the STS therapy between case reports and multi-case reports.
Data synthesis and statistical analysis

Definition of patients' clinical outcomes
The treatment effects of STS were classified as effective treatment, non-responding or deteriorating effects, and death. 10, 11 The effective treatment was defined as an improvement in skin lesion cicatrisation or pain relief without death. Nonresponding effects were defined as stable skin lesions without remission or exacerbation of the disease in patients who remained alive. All-cause mortality after STS treatment was defined as death due to exacerbations of calciphylaxis or other complications of advanced CKD. All reported adverse events after STS treatment were collected (nausea and vomiting, rhinorrhoea, peritonitis, hypotension, increased anion gap metabolic acidosis, and sepsis).
Subgroup analysis
As the descriptive approach may be inconsistent in case reports, and patient's situations were complex, a number of subgroup analyses were performed.
We assessed efficacy and safety of the STS therapy based on the following four reported STS administration methods, i.e. (i) intravenous injection (IV); (ii) intraperitoneal injection (IP); (iii) in dialysis session (ID); and (iv) combination therapy including intravenous injection and oral administration (IC).
2. A further subgroup analysis based on different type of concomitant calcification was also carried out, including coronary aortic calcification (CAC), abdominal aortic calcification (AAC), peripheral vascular calcification (PVC), skin vascular calcification (SVC), or other metastatic calcifications (OMC).
3. As patients with calciphylaxis are often treated in combination with other medications in clinical practice (e.g. calcium supplements, vitamin D analogues, calcimimetics and phosphate binders), clinical outcomes of the STS therapy were also analysed according to concomitant therapy.
Categorical variables were presented as frequency or percentage. Continuous variables were presented as mean (± standard deviation) or median (interquartile range) values. Categorical variables were compared between case reports and multiple case reports using Pearson (Table 1) . There were 64 patients in case reports with a mean age of 60 ± 15 years. 75% of patients were female. There were 294 patients in multi-case reports with a mean age of 57 ± 16 years. Again, they were female predominant (73.9%). The majority of patients underwent haemodialysis, which were seen in both case reports (57.8%) and multi-case reports (93.9%). The median dialysis vintage in case reports and multi-case reports was 61.8 months, 40.6 months, respectively (Table 1 ). There was no significant difference between case report and multi-case reports in baseline characteristics.
Most patients receiving STS intravenously were reported in both cases (70.3%) and multi-case reports (92.3%) ( Table 2) . The majority of patients were also treated with various adjunctive therapies before or during the STS treatment. In case reports, 26.6% calciphylactic patients were complicated by secondary hyperparathyroidism requiring PTX. The uses of cinacalcet (calcimimetic agent) and sevelamer (phosphate binder) accounted for 31.3% and 37.5% respectively. Similarly, a number of patients received PTX and cinacalcet (25% and 18.8%, respectively) in multi-case reports (Table 2) .
Treatment outcome
The efficacy of the STS therapy was 84.4% in case reports and 67.0% in multi-case reports (Table 2 and Fig. 1 ). The mortality rate following the STS therapy was 26.6% in case reports and 40.4% in multi-case reports. In case reports, 13/64 patients showed an improvement in calciphylactic lesion with STS treatment, however they died due to complications (e.g. ischaemic infarction, sepsis, gastrointestinal bleeding and other complications). Adverse events were reported in 25 patients, the most common one being nausea and vomiting (17.2%), followed by sepsis (14.1%), and metabolic acidosis (7.8%) ( Table 2 and Fig. S1 ). In multiple case reports, nausea and vomiting, and metabolic acidosis were reported at 30.4% and 14.8%, respectively ( Table 2) . IC, intravenous injection combination oral; ID, in dialysis session; IP, intraperitoneal injection; IV, intravenous injection; PTX, parathyroidectomy; -, indicates absence.
Fig. 1 Sodium thiosulphate (STS) treatment efficacy.
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Subgroup analysis
In the case reports, we divided the 64 patients into effectiveness group, non-responder group and death group according to the clinical outcomes. The average age of patients and proportion of women between effectiveness group and death groups were not significantly different (mean age 58 vs 65 years, P = 0.13; proportion of women: 75.6% vs 70.6%; P = 0.83) ( Table 3 ).
In view of the aetiology of ESKD, 29.2% of patients had diabetic nephropathy, 15.4% had primary glomerular diseases, and 7.7% had nephrolithiasis ( Figure S2 ).
1. Administration methods. STS doses reported in this review ranged from 5 to 25 g and STS were administered three times a week on average. [16] [17] [18] Intravenous administration of STS was the most common way of administration for calciphylactic patients (70.3%) with its treatment efficiency achieved to about 65.9%, In addition, 9.8% patients received IP and 11.1% received ID administration of STS, and five patients (7.3%) received STS intravenous injection in combination of oral tablets (IC). However, there was no significant difference in the treatment efficacy among different administration ways (P = 0.19) ( Table 4) . 2. Different types of calcification. All patients were presented with varying degrees of skin or vascular calcification (Table S1 ). 32.3% of patients also had evidence of other vascular calcification including AAC (12.5%), CAC (7.8%), PVC (25.0%) and OMC (9.4%). Among the different types of calcification, three of eight patients who had ≥ three types of calcification died (37.5%) after STS treatment, however, there was no significant difference in the mortality between patients with multiple types of calcification and patients with only one type of calcification (P = 0.41) ( Table 4 ). 3. Concomitant therapy. History of concomitant therapy was provided in around a third of case reports, including cinacalcet, sevelamer and PTX. The proportion of using these adjunctive therapies was not significantly different among the effectiveness, non-responder and death groups (Table 4) . T Peng et al.
DISCUSSION
Calciphylaxis is an uncommon complication 36 in advanced CKD but is associated with high mortality. 15, 55 In recent years, STS has been successfully used as an off-label drug in calciphylaxis. 7, 8 It has been used therapeutically for the chronic statue of measles, itchy skin disease, and as an antidote for cyanide poisoning. 56 When administered intravenously, STS distributes throughout extracellular fluids and normally is excreted unchanged in the urine. It could combine with insoluble tissue calcium salts to form calcium thiosulfate, which is thousands of times more soluble than many other calcium salts. 57 Our study, to our knowledge is the first study systematically reviewed current evidence on the effect of the STS therapy on calciphylaxis. It included 358 patients with calciphylaxis from previous reports. The majority of them were on long-term haemodialysis (87.4%). We found a successful response rate approached to about 70% with the STS therapy, including the largest report by Nigwekar et al. 11 Although 37.6% of our patients died even with continuously use of STS, the mortality rate was lower than patients who were not treated with STS (the mortality was 50% reported in earlier publication). 10 Furthermore, in 79 papers (271 patients) detailing the treatment and prognosis of calciphylactic patients, the efficacy and mortality rate of those patients were 24% and 50%, respectively. In our current review, the STS therapy was associated with higher efficacy rate (70%) and lower mortality rate (38%). However, we could not draw a conclusion that the better prognosis is contributed solely from the STS therapy because other factors such as an improvement of dialysis technology could also benefit the patients. Current literature shows that calciphylaxis is mainly associated with female gender, dialysis duration, hypercalcaemia, hyperphosphataemia and hyperparathyroidism. 58, 59 Female gender and long-standing haemodialysis appeared to be risk factors in our retrospective analysis. 70.3% patients in case reports and 92.3% in multi-case reports received intravenous injection (IV) of STS, implying that IV STS appeared to be the most common and acceptable mode of administration. However, patients with IV STS appeared to be more prone to sepsis (20%). In addition, IV STS can lead to changes in osmotic pressure, followed by the release of H ions, resulting in acidosis. 42 Previous literature suggested that intraperitoneal injection (IP) of STS was a cause of chemical peritonitis, 43 which was consistent with our findings (three of the six developed chemical peritonitis). The efficacy and mortality rate following the STS therapy in our study were also consistent to the previous literature. However, no significant difference in clinical responsive or mortality rate was noted among STS regimens, combination therapy, and adverse events between the case reports and multi-case reports in our review. We used the detailed data in the case reports to make an in-depth analysis of the indicators that may have an impact on STS outcomes.
Four predialysis patients in case reports remained alive. Concomitant CAC and AAC appeared to be associated with cardiovascular complication in calciphylactic patients. However, there was no significant association between calcified location and STS treatment effect. These results may be limited by insufficient CT scan reports in those included cases.
Secondary hyperparathyroidism is another risk factor for calciphylaxis. It causes hyperphosphataemia, then promotes the release of calcium and phosphate from the bone. 60 There were 26.6% patients receiving PTX reported in the case reports. In addition, 31.3% and 37.5% of the patients received cinacalcet and sevelamer therapy for secondary hyperparathyroidism and hyperphosphataemia, respectively. However, there was no difference in the incidence of calciphylaxis between medication combination group and STS monotherapy group, suggesting that the effect of STS may not be influenced by concomitant therapy for renal bone disease. Warfarin is a well-known risk factor for calciphylaxis, there were only seven patients on warfarin and two patients died after STS treatment in this review, due to the small number of cases, we cannot determine the influence of warfarin on outcomes from STS treatment. This review has the following limitations. Firstly, given that none of the included studies were randomized controlled trials, we were unable to assess unbiased treatment effects of STS among patients with calciphylaxis. Secondly, the outcome definitions have some heterogeneity around the groupings of event types. Due to the difficulty in performing a randomized controlled trial, a well-designed disease registry system remains a promising way to summarize the treatment strategies in calciphylaxis.
CONCLUSION
Calciphylaxis remains a serious complication and carries high mortality. Our study has reinforced the promising role of STS as an efficient therapy for calciphylaxis. Although the study was unable to assess the efficacy of sodium thiosulfate used alone in the treatment of calciphylaxis, it may represent an emerging component of most therapeutic strategies to treat this devastating condition. Further studies are warranted to evaluate STS effectiveness and understand the mechanisms in treating patients with calciphylaxis.
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